EPI Health, A Novan Company, Enters Exclusive License Agreement With Sato Pharmaceutical Co., Ltd. For RHOFADE In Japan; Under Agreement, EPI Will Receive $5M Upfront Payment, $2.5M Milestone Payment And Royalties On Net Sales
Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced that EPI Health, LLC, a fully consolidated subsidiary of Novan, has entered into an exclusive license agreement with Sato